MINI REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
This article is part of the Research TopicBiologics and Targeted Therapies for Autoimmune and Auto-inflammatory Dermatoses: Balancing Efficacy with Safety and ToxicityView all 17 articles
Super Responders to Biologic Therapy in Psoriasis: Definitions, Predictors, and Implications for Precision Medicine
Provisionally accepted
- 1Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- 2Department of Dermatology, Weifang People's Hospital, Weifang, China
- 3Department of Nuclear Medicine, Weifang People's Hospital, Weifang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Biologic therapies have revolutionized psoriasis management, yet treatment responses remain highly heterogeneous. A distinct subgroup of patients, termed super responders (SRs), achieves exceptionally rapid, complete, and sustained responses to biologic therapies. Understanding this phenotype is critical for advancing precision medicine in psoriasis. This review summarizes the latest advances in SRs, focusing on definitions, predictors, and therapeutic implications. The definition of SRs vary widely across studies, differing in both temporal criteria and efficacy endpoints. Meanwhile, emerging evidence suggests a convergent trend toward multidimensional definitions that combine rapid, complete initial skin clearance, typically PASI 100 within 3 to 6 months, with sustained low disease activity over time. Convergent predictors of SRs include a lower body mass index (BMI), a favorable metabolic profile, biologic-naïve status and emerging genetic and immunological markers. As a biologically distinct subgroup, identifying SRs provides a unique opportunity for treatment optimization, including dosing-interval extension and treatment-free remission in selected patients, offering the potential to sustain efficacy while reducing drug exposure, cost, and patient burden. Key research priorities include establishing consensus definitions, developing validated predictive models, and generating long-term safety data to guide treatment optimization. Integrating the SRs concept into practice may transform psoriasis care from fixed, lifelong regimens to adaptive, evidence-based management grounded in precision medicine.
Keywords: biologic therapy, precision medicine, predictive biomarkers, Psoriasis, Super responders
Received: 12 Nov 2025; Accepted: 10 Feb 2026.
Copyright: © 2026 Peng, Wang and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kun Han
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.